Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medexus Pharmaceuticals Inc
T.MDP
Alternate Symbol(s):
MEDXF
Healthcare
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its...
lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(1993)
•••
lscfa
X
Post by
lscfa
on Nov 08, 2024 1:02pm
$100M shelf prospectus filed
On sedar.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 18, 2024 5:01pm
New Press Release - Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March...
read article.
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 06, 2024 10:42am
New Press Release - Canadian Investment Regulatory Organization Trading Halt - MDP
TORONTO, June 6, 2024 /CNW/ - The following issues have been halted by CIRO:Company: Medexus Pharmaceuticals Inc.TSX Symbol: MDPAll Issues: YesReason: Pending NewsHalt Time (ET): 10:03 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 06, 2024 10:35am
New Press Release - Canadian Investment Regulatory Organization Trade Resumption - MDP
TORONTO, June 6, 2024 /CNW/ - Trading resumes in:Company: Medexus Pharmaceuticals Inc.TSX Symbol: MDPAll Issues: YesResumption (ET): 11:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 06, 2024 10:19am
New Press Release - FDA Accepts for Review Treosulfan NDA Resubmission
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for...
read article.
(287)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 11:11pm
RE:RE:This article favor Treo over busulfan
Published on May 26, 2022, announced NDA resubmission on July 25, 2022, FDA rejected on September x https://onlinelibrary.wiley.com/doi/10.1002/ajh.26620
(287)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 10:47pm
RE:RE:RE:This article favor Treo over busulfan
On treosulfan, we are pleased to report that the data collection phase of medac's effort to respond to the FDA's information requests on treosulfan is now complete," Mr d'Entremont
...more
(287)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 10:40pm
RE:RE:This article favor Treo over busulfan
An NDA includes all animal and human data and analyses of the data, as well as information about how the drug behaves in the body and how it is manufactured. When an NDA comes in, the FDA has 60 days
...more
(287)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 10:26pm
RE:This article favor Treo over busulfan
The second published by nature favor Treo https://www.nature.com/articles/s41409-024-02269-4
(287)
•••
Napcoo
X
Post by
Napcoo
on May 21, 2024 10:12pm
This article favor Treo over busulfan
https://www.nature.com/articles/s41409-023-02135-9
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 02, 2024 7:31am
New Press Release - Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.Event: 2024...
read article.
(287)
•••
Napcoo
X
Comment by
Napcoo
on Mar 29, 2024 9:00pm
RE:Trend Continues
He is just trying to earn a living, there isn't any truth out of him
(8)
•••
TheMedia
X
Post by
TheMedia
on Mar 29, 2024 3:34pm
Trend Continues
March26th Equity Guru/Chris Parry writes up the company. Another company suckered out of their money by this scam out-fit. Stocks do nothing but lose money for anyone following this useless out-fit.
(287)
•••
Napcoo
X
Comment by
Napcoo
on Mar 28, 2024 6:50pm
RE:RE:Ixinity replacement therapy
Gene therapy needs time to verify the long term results, giving replacement therapy such as ixinity a break https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b
(287)
•••
Napcoo
X
Comment by
Napcoo
on Mar 28, 2024 6:40pm
RE:RE:Ixinity replacement therapy
FDA-approved gene therapies In November 2022, the Food and Drug Administration approved Hemgenix, CSL Behring's hemophilia B gene therapy. Researchers at Children’s Hospital of Philadelphia are
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden